KRAS oncogene substitutions in Korean NSCLC patients: Clinical implication and relationship with pAKT and RalGTPases expression

Lung Cancer

Volumn 85, Issue 2, 2014, Pages 299-305

  Kim, Eun Young ^a   Kim, Arum ^a   Kim, Se Kyu ^a   Kim, Hyung Jung ^a   Chang, Joon ^a   Ahn, Chul Min ^a   Lee, Jae Seok ^a   Shim, Hyo Sup ^a   Chang, Yoon Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

KRAS; NSCLC; PAKT; RalA; RalB; RalGTPases

Indexed keywords

GUANOSINE TRIPHOSPHATASE; PROTEIN KINASE B; RAL PROTEIN; CODON;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CODON; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MUTANT; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; WILD TYPE; AMINO ACID SUBSTITUTION; CANCER STAGING; GENE EXPRESSION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH KOREA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; CARCINOMA, NON-SMALL-CELL LUNG; CODON; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-AKT; RAL GTP-BINDING PROTEINS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84904102665     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.04.012     Document Type: Article

References (34)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA: Cancer J Clin 2012, 62:10-29.
2. Der C.J., Krontiris T.G., Cooper G.M. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci U S A 1982, 79:3637-3640.
3. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta 2005, 1756:81-82.
4. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
5. Andreyev H.J., Norman A.R., Cunningham D., Oates J.R., Clarke P.A. Kirsten ras mutations in patients with colorectal cancer: the multicenter RASCAL study. J Natl Cancer Inst 1998, 90:675-684.
6. Siegfried J.M., Gillespie A.T., Mera R., Casey T.J., Keohavong P., Testa J.R., et al. Prognostic value of specific KRAS mutations in lung adenocarcinomas. Cancer Epidemiol Biomarkers Prev 1997, 6:841-847.
7. Riely G.J., Kris M.G., Rosenbaum D., Marks J., Li A., Chitale D.A., et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008, 14:5731-5734.
8. Bae N.C., Chae M.H., Lee M.H., Kim K.M., Lee E.B., Kim C.H., et al. ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet 2007, 173:107-113.
9. Kim Y.T., Kim T.-Y., Lee D.S., Park S.J., Park J.-Y., Seo S.-J., et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer 2008, 59:111-118.
10. Soung Y., Lee J., Kim S., Seo S., Park W., Nam S., et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 2005, 446:483-488.
11. Jang T.W., Oak H.K., Chang H.K., Suo S.J., Jung M.H. EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung. Korean J Intern Med 2009, 24:48-54.
12. Soung Y.H., Kim S.Y., Seo S.H., Park W.S., Nam S.W., Song S.Y., et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 2005, 446:483-488.
13. Ihle N.T., Byers L.A., Kim E.S., Saintigny P., Lee J.J., Blumenschein G.R., et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012, 104:228-239.
14. Rodenhuis S., Slebos R.J., Boot A.J., Evers S.G., Mooi W.J., Wagenaar S.S., et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988, 48:5738-5741.
15. Ferretti G., Curigliano G., Pastorino U., Cittadini A., Flamini G., Calabro M.G., et al. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. Clin Cancer Res 2000, 6:2393-2400.
16. Shepherd F.A., Domerg C., Hainaut P., Jänne P.A., Pignon J.-P., Graziano S., et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013, 31:2173-2181.
17. Meng D., Yuan M., Li X., Chen L., Yang J., Zhao X., et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer 2013, 81:1-10.
18. Beau-Faller M., Legrain M., Voegeli A.C., Guerin E., Lavaux T., Ruppert A.M., et al. Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer 2009, 100:985-992.
19. Qiu T., Ling Y., Chen Z., Shan L., Guo L., Lu N., et al. Comparison of real-time PCR-optimized oligonucleotide probe method and Sanger sequencing for detection of KRAS mutations in colorectal and lung carcinomas. Zhonghua Bing Li Xue Za Zhi 2012, 41:599-602.
20. Tsurutani J., Fukuoka J., Tsurutani H., Shih J.H., Hewitt S.M., Travis W.D., et al. Evaluation of two phosphorylation sites improves the prognostic significance of akt activation in non-small-cell lung cancer tumors. J Clin Oncol 2006, 24:306-314.
21. Villaruz L.C., Socinski M.A., Cunningham D.E., Chiosea S.I., Burns T.F., Siegfried J.M., et al. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma. Cancer 2013, 119:2268-2274.
22. Shipitsin M., Feig L.A. RalA but not RalB enhances polarized delivery of membrane proteins to the basolateral surface of epithelial cells. Mol Cell Biol 2004, 24:5746-5756.
23. Lopez J.A., Kwan E.P., Xie L., He Y., James D.E., Gaisano H.Y. The RalA GTPase is a central regulator of insulin exocytosis from pancreatic islet beta cells. J Biol Chem 2008, 283:17939-17945.
24. Chen X.-W., Leto D., Chiang S.-H., Wang Q., Saltiel A.R. Activation of RalA is required for insulin-stimulated Glut4 trafficking to the plasma membrane via the exocyst and the motor protein Myo1c. Dev Cell 2007, 13:391-404.
25. Chen X.-W., Leto D., Xiong T., Yu G., Cheng A., Decker S., et al. A Ral GAP complex links PI 3-kinase/Akt signaling to RalA activation in insulin action. Mol Biol Cell 2011, 22:141-152.
26. Lalli G. RalA and the exocyst complex influence neuronal polarity through PAR-3 and aPKC. J Cell Sci 2009, 122:1499-1506.
27. Lalli G., Hall A. Ral GTPases regulate neurite branching through GAP-43 and the exocyst complex. J Cell Biol 2005, 171:857-869.
28. Chien Y., White M.A. RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival. EMBO Rep 2003, 4:800-806.
29. Lim K.-H., O'Hayer K., Adam S.J., Kendall S.D., Campbell P.M., Der C.J., et al. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol 2006, 16:2385-2394.
30. Rossé C., Hatzoglou A., Parrini M.-C., White M.A., Chavrier P., Camonis J. RalB mobilizes the exocyst to drive cell migration. Mol Biol Cell 2006, 26:727-734.
31. Wang H., Owens C., Chandra N., Conaway M.R., Brautigan D.L., Theodorescu D. Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Res 2010, 70:8760-8769.
32. Chien Y., Kim S., Bumeister R., Loo Y.-M., Kwon S.W., Johnson C.L., et al. RalB GTPase-mediated activation of the IκB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 2006, 127:157-170.
33. Bodemann B.O., Orvedahl A., Cheng T., Ram R.R., Ou Y.-H., Formstecher E., et al. RalB and the exocyst mediate the cellular starvation response by direct activation of autophagosome Assembly. Cell 2011, 144:253-267.
34. Peschard P., McCarthy A., Leblanc-Dominguez V., Yeo M., Guichard S., Stamp G., Marshall Christopher J. Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis. Curr Biol 2012, 22:2063-2068.